Biomaxima (BMX) fair value: what the stock is really worth
As of Oct 29, 2026: fair value (intrinsic value) of Biomaxima stock PLN 6.88, price PLN 9.50, upside -27.6%, quality 57 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 29, 2026.
How to read this chart
60‑month range 9.30 PLN – 37.48 PLN · fair‑value band 4.00 PLN – 6.88 PLN · the 9.50 PLN price screens above the 6.88 PLN fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 29, 2026.
Follow Biomaxima in your weekly email
Every Wednesday you see whether Biomaxima is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
BioMaxima S.A. produces and distributes microbiological media, reagents, and in vitro diagnostic equipment in Poland. It offers microbiology products, including ready to use media, such as plates, bottles, bags, and media in tubes; dehydrated media; agars and peptones; and supplements.
Show moreShow less
The company also provides molecular biology and cell culture products which includes real time PCR, nucleic acid isolation, NA and PCR electrophoresis, protein electrophoresis, enzymes, antibiotics, agaroses and molecular biology media, media and buffers for in vitro cultures, phenotypic micromatrices, plastics and small equipment, basic substrate components, and form.
In addition, it offers laboratory diagnostics solutions for various areas of clinical chemistry, haematology, coagulology, immunochemistry, POCT, rapid tests, and blood collection systems; and disposable materials comprising microbiology, dispensing equipment, tubes, plugs, tripods, capillaries, equipment, aspiration-vacuum system, containers, tank for analysers, urine analysis, microscope slides, reagent tubes, autoclave equipment, and pliers and scissors.
BioMaxima S.A. was founded in 1997 and is headquartered in Lublin, Poland.
Stock analysis
Biomaxima (BMX) currently trades at 9.50 PLN, while our model-based Fair Value estimate is 6.88 PLN, 27.6% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of 7.59 PLN per share, and 6 of the 21 models we run sit above the 9.50 PLN price.
Bear case: the Multiples group reads lowest at 1.11 PLN, and 15 of the 21 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 4.00 PLN (bear) to 6.88 PLN (bull), the price of 9.50 PLN sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Biomaxima reported revenue of 60.9M PLN in FY2025 versus 79.1M PLN in FY2021, a compound −6.3%/yr. Reported net income was 105K PLN in FY2025, compounding −68.2%/yr from FY2021.
Key figures
Market cap 39.8M PLN (≈ $10.1M) Micro · P/E ratio 45.2 · P/S ratio 0.67 · EPS (TTM) 0.2100 PLN · Net margin 1.3% · Return on equity 1.7% · Return on assets (EBIT) 14.3% · Operating margin 0.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (low confidence).
What moves the price
The share trades about 28% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −10% fair-value upside, at −28%, BMX screens richer than that median.
Fair Value models
Bear4.00 PLNFair Value 6.88 PLNBull6.88 PLN
Price 9.50 PLN · Upside -27.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.1738 PLN per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+15.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−24.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.2%
Start year 2020 (pandemic). Over 10 years: +10.7% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−58.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−58.6%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−58.6% vs −22.7%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.17% → 0%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+20.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Poland: IMF forecast 3.1% a year to 2030, 4.6% from 2016 to 2025) that is about +16.4% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 121 stocks
Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score57 · Above median
Fair Value upside−29.1% · Above median
Profitability
Return on equity (12 months)1.7% · Below median
Return on assets0.1% · Below median
Net margin (12 months)1.3% · Below median
Operating margin (12 months)0.8% · Below median
Growth and dividend
Revenue growth (quarter YoY)7.0% · Below median
Balance sheet
Debt / equity0.14× · Above median
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/E (12 months)45.2× · Pricier than median
P/B0.85× · Cheapest 25%
P/S (12 months)0.67× · Cheapest 25%
Price / free cash flow30.4× · Pricier than median
EV/EBITDA10.2× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)35· sector 40
PAST (return on equity)7· sector 14
HEALTH (low debt)93· sector 95
DIVIDEND (yield)0· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Biomaxima Fair Value". https://www.fairvalue-calculator.com/stock/BMX
Frequently asked questions
Is Biomaxima (BMX) overvalued or undervalued?
As of Oct 29, 2026, our model estimates a fair value of 6.88 PLN versus a price of 9.50 PLN, about −28% upside (overvalued).
What is the fair value of BMX?
Our model-based fair value for Biomaxima is 6.88 PLN (as of Oct 29, 2026), built from audited fundamentals. The current price: 9.50 PLN.
What is the quality score of BMX?
Biomaxima has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Biomaxima (BMX)?
Our model-based price target is the fair value of 6.88 PLN (as of Oct 29, 2026) from 21 valuation models. Cautious scenario 4.00 PLN, optimistic scenario 6.88 PLN. It is a calculation from audited fundamentals, not an analyst target.
What is the Biomaxima stock forecast for 2026?
Our models put fair value at 6.88 PLN, about −28% upside versus a price of 9.50 PLN (overvalued). Cautious scenario 4.00 PLN, optimistic scenario 6.88 PLN. The calculation is refreshed regularly with new filings.
What is the revenue of Biomaxima (BMX)?
Biomaxima reported trailing-twelve-month revenue of about 60.6M PLN (latest available figure, as of Oct 29, 2026).
What growth is priced into Biomaxima (BMX)?
For today's price to be fair in a discounted-cash-flow model, Biomaxima would have to grow free cash flow by +20.0 % per year for five years (discount rate 9.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -0.2 % per year. As of Oct 29, 2026.
What discount rate (WACC) does the fair value of BMX use?
Our models discount Biomaxima at 9.3 %: a base by market capitalisation (nano), damped by beta 0.28, country premium for Poland. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Biomaxima that is +20.0 % per year a year over ten years, using the same discount rate (9.3 %) and the same formula as our fair value.
How much growth has Biomaxima (BMX) delivered so far?
Over the past 5 years revenue at Biomaxima grew -0.2 % a year. The price currently implies +20.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Biomaxima (BMX) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Biomaxima (+20.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Biomaxima (BMX)?
The free-cash-flow yield on the price is 3.36 %: that much free cash flow Biomaxima produces per unit of market value. When it exceeds the discount rate of our models (9.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Biomaxima (BMX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Biomaxima it is 6.88 PLN per share (as of Oct 29, 2026), against a price of 9.50 PLN. It is the blended result of 21 valuation models (cash flow, earnings, asset, dividend).
Is Biomaxima stock overvalued or undervalued in 2026?
As of Oct 29, 2026, BMX trades above its calculated fair value: price 9.50 PLN, fair value 6.88 PLN, a gap of about −28% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BMX?
No. The price is what the market pays today (9.50 PLN); the fair value is what the company's own numbers justify (6.88 PLN). For Biomaxima the two are 2.62 PLN per share apart. That gap is exactly why we show both numbers side by side.
How much is Biomaxima worth?
The market values Biomaxima at about 39.8M PLN (market capitalisation, as of Oct 29, 2026). Per share that is 9.50 PLN; our models calculate a fair value of 6.88 PLN per share.
What do the bullish and bearish scenarios say about BMX?
Our models span a range for Biomaxima: cautious scenario 4.00 PLN, base 6.88 PLN, optimistic 6.88 PLN per share (as of Oct 29, 2026, price 9.50 PLN). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BMX?
Biomaxima trades at a price-to-earnings ratio of 45.2 (as of Oct 29, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 6.88 PLN is built from several models across several years. Median P/E at fiscal year-end, 8 fiscal years (2016 to 2025), reported earnings: 19.0. Other multiples: P/B 0.9, P/S 0.7, EV/EBITDA 10.2.
How solid is the balance sheet of Biomaxima (BMX)?
Balance-sheet figures for Biomaxima (as of Oct 29, 2026): return on equity 1.7%, debt of 0.14 per unit of equity. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is BMX from its 52-week high?
Biomaxima trades at 9.50 PLN, about 28% below its 52-week high of 13.25 PLN and 2% above the low of 9.30 PLN (as of Oct 29, 2026). Distance from the high says nothing about value: that is what the fair value of 6.88 PLN is for.
Which stocks are comparable to Biomaxima?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Biomaxima stock attractive at the current price?
The data as of Oct 29, 2026: price 9.50 PLN, calculated fair value 6.88 PLN (−28%), Quality Score 57/100, from 21 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BMX calculated?
We run Biomaxima through 21 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 6.88 PLN, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. Biomaxima itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Biomaxima (BMX)?
The closing price on Oct 29, 2026 was 9.50 PLN. Our model-based fair value is 6.88 PLN, about −28% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Biomaxima right now?
The price sits above even our optimistic bull case (6.88 PLN). The favourable scenario is already priced in. Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Biomaxima
How large is the market capitalisation of Biomaxima (BMX)?
The market capitalisation of Biomaxima is 39.8M PLN (≈ $10.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Biomaxima (BMX)?
The price-to-sales ratio of Biomaxima is 0.67 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Biomaxima (BMX)?
Earnings per share at Biomaxima are 0.2100 PLN (price ÷ EPS = P/E 45.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Biomaxima (BMX)?
The net margin of Biomaxima is 1.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Biomaxima (BMX)?
The return on equity (ROE) of Biomaxima is 1.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Biomaxima (BMX)?
On an EBIT basis the return on assets of Biomaxima is 14.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Biomaxima (BMX)?
The operating margin of Biomaxima is 0.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Biomaxima (BMX)?
Revenue at Biomaxima is growing +7.0% versus a year earlier (3y avg −24.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Biomaxima (BMX)?
Earnings per share at Biomaxima are growing −44.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Biomaxima (BMX) carry?
The net debt of Biomaxima is 12.7M PLN (fiscal year 2025, ≈ 9.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Biomaxima in the live analysis
One click puts Biomaxima on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Some data
Oct 29, 2026